Leukemia, Myeloid, Acute: all 3,035 studies
Page 17 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingNCT05455294Phase 1
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed TherapiesActive, not recruitingNCT05453903Phase 1
- G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT05449899Phase 2/3
- A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSStatus unknownNCT05448599Phase 1/2
- Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid LeukemiaStatus unknownNCT05445765Phase 1
- CART-38 in Adult AML and MM PatientsTerminatedNCT05442580Phase 1
- Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT05441514Phase 1
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesActive, not recruitingNCT05428969Phase 1/2
- A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer SurvivorsActive, not recruitingNCT05428176Not applicable
- Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesStatus unknownNCT05426798Phase 1
- A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in CanadaTerminatedNCT05424562
- An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionActive, not recruitingNCT05413018Phase 2
- Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
- Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingNCT05396859Phase 1
- FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.Status unknownNCT05383014
- Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 1
- A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
- Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
- Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaStatus unknownNCT05362942Phase 2
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesActive, not recruitingNCT05362773Phase 1
- Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedNCT05361057Phase 2
- ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)TerminatedNCT05358808Phase 2
- Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaActive, not recruitingNCT05356169Phase 2/3
- A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaTerminatedNCT05345938Phase 1/2
- Donor Immune Cell Therapy for Acute Myeloid LeukemiaStatus unknownNCT05333705Phase 1
- GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
- Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05330364Phase 2
- Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory LeukemiasWithdrawnNCT05321940Phase 1
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
- Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedNCT05319587Phase 1/2
- A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceCompletedNCT05317494
- Real World Outcomes Using Novel Agents for AML in the UKStatus unknownNCT05312112
- A Long-term Follow-up Study of Patients Who Received VOR33TerminatedNCT05309733
- Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid AcidStatus unknownNCT05297123Phase 1
- Pyronaridine in Acute Myeloid Leukemia (AML)SuspendedNCT05291390Phase 2
- Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT05266950Phase 1
- Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After TransplantationStatus unknownNCT05266274Not applicable
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid LeukemiaSuspendedNCT05263284Phase 1
- Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic SyndromeTerminatedNCT05263271Phase 1
- Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive ChemotherapyStatus unknownNCT05249894
- Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT05248685Phase 1
- NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05247957Not applicable
- Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid LeukemiaWithdrawnNCT05246384Phase 1/2
- Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Active, not recruitingNCT05233618Phase 1
- An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid LeukemiaActive, not recruitingNCT05226468Phase 1
- Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)TerminatedNCT05223699Phase 1
- Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxActive, not recruitingNCT05222984Phase 1
- Managed Access Programs for PKC412, MidostaurinNo longer availableNCT05219266
- A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
- A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax TabletsCompletedNCT05215639
- Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid LeukemiaStatus unknownNCT05215015Early Phase 1
- A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic MalignanciesWithdrawnNCT05201183Phase 1/2
- A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AMLActive, not recruitingNCT05199051Phase 2
- A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCECompletedNCT05193448
- Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly PatientsCompletedNCT05188326Phase 3
- Cryopreserved MMUD BM With PTCy for Hematologic MalignanciesWithdrawnNCT05170828Phase 1
- CPX-351 Real-World Effectiveness and Safety StudyCompletedNCT05169307
- A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.CompletedNCT05155709Phase 1
- Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyStatus unknownNCT05154474
- Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedNCT05153330Phase 1
- Muscle Dysfunction in Patients With Haematological DiseasesActive, not recruitingNCT05150561
- Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in LeukemiaCompletedNCT05149339Phase 1/2
- A Study of BTX-1188 in Subjects With Advanced MalignanciesTerminatedNCT05144334Phase 1
- Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaActive, not recruitingNCT05144243Phase 4
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05139004Phase 1
- RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.Status unknownNCT05127798
- Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction TherapiesStatus unknownNCT05123352
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic MalignancyActive, not recruitingNCT05104775Phase 1
- A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Status unknownNCT05100303Phase 1/2
- A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05077423Phase 1
- Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCTStatus unknownNCT05066958Phase 1/2
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status unknownNCT05061147Phase 1/2
- Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival OutcomesCompletedNCT05057299
- Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLTerminatedNCT05054543Phase 3
- Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLStatus unknownNCT05053425Not applicable
- Pharmacokinetics, Tolerability and Safety of NEX-18aCompletedNCT05048498Phase 1
- Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid LeukemiaStatus unknownNCT05042531Not applicable
- Anti-Leukemia Immune Responses After Irradiation of Extramedullary TumorsActive, not recruitingNCT05035706Early Phase 1
- New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT05029141Phase 2
- Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream InfectionStatus unknownNCT05016752
- Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05016063Early Phase 1
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCTActive, not recruitingNCT05015426Phase 1
- Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05008575Phase 1
- Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid LeukemiaActive, not recruitingNCT05001828Phase 1
- Study of GDX012 in Patients With MRD Positive AMLTerminatedNCT05001451Phase 1
- Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT04994808Phase 2
- Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative NeoplasmCompletedNCT04992949Phase 2
- Induction Therapy for Patients With FLT3 Mutated Acute Myeloid LeukemiaWithdrawnNCT04982354Phase 1/2
- A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04980885Phase 1/2
- Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT04975919Phase 2
- Oral Health Condition and Quality of Life in Children With LeukemiaTerminatedNCT04968860
- Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First RemissionActive, not recruitingNCT04968015Phase 2
- Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaTerminatedNCT04964505Phase 1
- Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT04956042Phase 1/2
- Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AMLActive, not recruitingNCT04953780Phase 1
- Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic SyndromesTerminatedNCT04951778Phase 1
- A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04946890Phase 1/2
- Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid MalignanciesCompletedNCT04943757Phase 2